Fundamental analysis · SEC EDGAR · TTM through 31/07/2026
MDT · NYSE · Healthcare
Fundamental quality
67
out of 100
Medtronic Plc runs like a cash machine: it converts about 16.3% of revenue into free cash flow and holds a 13.9% net margin, though it grows at a measured pace. On fundamental quality it scores 67 out of 100, profiling it as a company of reasonable quality. Its weakest area is its growth (revenue +4.3%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Medtronic is one of the world's largest medical-device makers: pacemakers, insulin pumps, neurostimulators and surgical robotics. Its scale and presence in dozens of countries give it the steady demand typical of healthcare.
EPS growth: 8.4% · Revenue growth: 4.3%
Net margin: 13.9% · ROE: 10.4% · ROIC: 7.1%
Net debt/EBITDA: 2.72x · FCF: 16.3%
Source: SEC EDGAR · TTM through 31/07/2026
The score includes +4 for dividend strength: 50 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | 30,117 | 3,606 | 4,885 | 22,796 |
| 2022 | 31,686 | 5,039 | 5,978 | 20,400 |
| 2023 | 31,227 | 3,758 | 4,580 | 22,821 |
| 2024 | 32,364 | 3,676 | 5,200 | 23,740 |
| 2025 | 33,537 | 4,662 | 5,185 | 26,298 |
| 2026 | 36,364 | 4,801 | 5,426 | 26,012 |
Between 2021 and 2026, revenue went from $30,117M to $36,364M (+21%) and net income went from $3,606M to $4,801M (+33%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the quarter ended July 31, 2026, versus the quarter ended July 25, 2025 (SEC filings):
Compared with the previous close (April 24, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$2.84
per share, yearly
75.8% of earnings
Payout
50 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Medtronic Plc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Medtronic Plc a good company to invest in?
In terms of business quality, Medtronic Plc scores 67 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Medtronic Plc a profitable company?
Yes. Medtronic Plc shows a net margin of 13.9% and an ROE of 10.4%, a sign of a profitable business.
Does Medtronic Plc have a lot of debt?
A moderate level: its net debt is 2.72 times its EBITDA.
Is Medtronic Plc growing?
Its revenue has grown 4.3% annualized in recent years and its earnings per share 8.4%.
Does Medtronic Plc generate cash?
Yes. It converts about 16.3% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Illumina (ILMN) · Zimmer Biomet (ZBH) · Baxter International (BAX) · Cardinal Health (CAH) · Cencora (COR) · Humana (HUM) · see more →
The best Healthcare stocks by our model →
Who's behind the methodology and model · how the score is computed
Data: see Medtronic Plc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.